{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["12"],"submitter":["Di Cosimo S"],"pubmed_abstract":["<h4>Importance</h4>Despite people with impaired immune competence due to an underlying disease or ongoing therapy, hereinafter frail patients, are (likely to be) the first to be vaccinated, they were usually excluded from clinical trials.<h4>Objective</h4>To report adverse reactions of frail patients after receipt of the third dose (booster) administered after completion of a two-dose mRNA vaccination and to compare with those reported after the receipt of the first two doses.<h4>Design</h4>A multicenter, observational, prospective study aimed at evaluating both the safety profile and the immune response of Pfizer-BioNTech or Moderna vaccines in frail patients.<h4>Setting</h4>National Project on Vaccines, COVID-19 and Frail Patients (VAX4FRAIL).<h4>Participants</h4>People consenting and in"],"journal":["Frontiers in oncology"],"pagination":["1002168"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9631315"],"repository":["biostudies-literature"],"pubmed_title":["Safety of third dose of COVID-19 vaccination in frail patients: Results from the prospective Italian VAX4FRAIL study."],"pmcid":["PMC9631315"],"pubmed_authors":["Costantini M","Ciliberto G","Salvarani C","Baldanti F","Locatelli F","Delcuratolo S","Uccelli A","Agrati C","Apolone G","Morrone A","Ciceri F","Di Cosimo S","Mantegazza R","Zinzani PL","Mantovani A","Lupo-Stanghellini MT","Silvestris N"],"additional_accession":[]},"is_claimable":false,"name":"Safety of third dose of COVID-19 vaccination in frail patients: Results from the prospective Italian VAX4FRAIL study.","description":"<h4>Importance</h4>Despite people with impaired immune competence due to an underlying disease or ongoing therapy, hereinafter frail patients, are (likely to be) the first to be vaccinated, they were usually excluded from clinical trials.<h4>Objective</h4>To report adverse reactions of frail patients after receipt of the third dose (booster) administered after completion of a two-dose mRNA vaccination and to compare with those reported after the receipt of the first two doses.<h4>Design</h4>A multicenter, observational, prospective study aimed at evaluating both the safety profile and the immune response of Pfizer-BioNTech or Moderna vaccines in frail patients.<h4>Setting</h4>National Project on Vaccines, COVID-19 and Frail Patients (VAX4FRAIL).<h4>Participants</h4>People consenting and in","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022","modification":"2026-05-28T03:07:59.022Z","creation":"2024-11-12T17:42:00.147Z"},"accession":"S-EPMC9631315","cross_references":{"pubmed":["36338743"],"doi":["10.3389/fonc.2022.1002168"]}}